SMA Therapeutics: A Comparative Overview of Drugs Approved and in Development

Sponsored By:

August 1, 2017
Targets for Therapeutic Intervention in SMA

**Decrease in SMN protein due to SMN1 gene deletion or mutation**

- **Strategy**: Provide functional SMN1 gene
- **Mechanism**: Gene replacement using a viral vector to deliver SMN1 gene to cells
- **Therapy**: AVXS-101

**Loss of motor neurons**

- **Strategy**: Increase SMN mRNA and protein from SMN2 gene
- **Mechanism**: Modify SMN2 mRNA splicing to increase amount of functional SMN protein
- **Therapy**: SPINRAZA, RG7916 branaplam

**Muscle weakness/atrophy**

- **Strategy**: Prevent motor neuron death
- **Mechanism**: Maintain mitochondria integrity in neurons
- **Therapy**: olesoxime

**INCREASES SMN PROTEIN**

**SMN INDEPENDENT**

- **Strategy**: Increase muscle strength and endurance
- **Mechanism**: Fast skeletal muscle troponin activator amplifies muscle response to nerve
- **Therapy**: CK-2127107
<table>
<thead>
<tr>
<th>Mechanism</th>
<th>Increases SMN</th>
<th>SMN Independent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strategy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug Type</td>
<td>Gene Therapy</td>
<td>SMN2 Splicing Modifier</td>
</tr>
<tr>
<td>Delivery Method</td>
<td>IV</td>
<td>Intrathecal</td>
</tr>
<tr>
<td>Dosing</td>
<td>One Time</td>
<td>Once Weekly</td>
</tr>
<tr>
<td>Body Distribution</td>
<td>Systemic</td>
<td>CNS Only</td>
</tr>
<tr>
<td>Current Target Population</td>
<td>Type I</td>
<td>Approved All Types</td>
</tr>
<tr>
<td>Drug</td>
<td>Clinical Safety Profile</td>
<td></td>
</tr>
<tr>
<td>--------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>AVXS-101 (AveXis)</td>
<td>Results from a Phase 1 study in SMA Type I patients demonstrate that AVXS-101 appears to be well-tolerated, with a favorable safety profile¹.</td>
<td></td>
</tr>
<tr>
<td>SPINRAZA (Biogen)</td>
<td>SPINRAZA demonstrated a favorable safety profile in Phase 1-3 clinical trials²,³. For additional safety information please see SPINRAZA prescribing information⁴.</td>
<td></td>
</tr>
<tr>
<td>RG7916 (Roche)</td>
<td>Clinical studies in healthy volunteers and SMA patients demonstrated that RG7916 was safe and well-tolerated at all doses studied⁵,⁶.</td>
<td></td>
</tr>
<tr>
<td>branaplam (Novartis)</td>
<td>A Phase 1/2 study in Type I SMA patients is currently underway that tests the safety of branaplam (LMI070)⁷.</td>
<td></td>
</tr>
<tr>
<td>olesoxime (Roche)</td>
<td>In a Phase 2 clinical trial in Type 2 and non-ambulatory Type 3 SMA patients, olesoxime was found to be safe at the doses studied for the duration of the trial⁸.</td>
<td></td>
</tr>
<tr>
<td>CK-2127107 (Cytokinetics)</td>
<td>Five Phase 1 studies of CK-2127107 have been completed and there were no safety concerns based on data from exposure in healthy volunteers⁹.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Drug</th>
<th>Patient Population and Developmental Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>AVXS-101 (AveXis)</td>
<td>Phase 1 study in Type I patients is ongoing¹⁰; plans to initiate a Phase 1 study via intrathecal delivery in Type II patients and a pivotal trial in Type I patients via intravenous delivery¹¹. Some patients may not be eligible for gene transfer therapy due to preexisting antibodies for the AAV9 virus¹⁰,¹¹,¹².</td>
</tr>
<tr>
<td>SPINRAZA (Biogen)</td>
<td>Approved for all SMA Type patients in U.S., E.U., Japan and Canada following a sham-controlled trial. Expanded access program for Type I patients is available¹³,¹⁴,¹⁵.</td>
</tr>
<tr>
<td>RG7916 (Roche)</td>
<td>Currently being tested in Phase 2 trials in patients with Type I, II, III¹⁶.</td>
</tr>
<tr>
<td>branaplam (Novartis)</td>
<td>Currently being tested in Phase 1/2 trial in Type I patients⁷.</td>
</tr>
<tr>
<td>olesoxime (Roche)</td>
<td>Phase 2 trial in Type II and III patients was completed⁸.</td>
</tr>
<tr>
<td>CK-2127107 (Cytokinetics)</td>
<td>Currently being tested in Phase 2 trial in Type II, III, IV patients¹⁷.</td>
</tr>
</tbody>
</table>
Glossary

**SMN Upregulating**
Drug acts through a mechanism to increase SMN protein levels. SMA is caused by the reduced levels of SMN protein.

**SMN Independent**
Drug acts through a mechanism that does not increase SMN protein levels.

**SMN Gene Replacement**
AXVS-101 uses a non-pathogenic adeno-associated virus (AAV9) containing the SMN1 transgene\(^\text{18}\). The virus is designed to deliver the gene to cells and provides constitutive, long-term SMN expression\(^\text{19}\).

**SMN2 Splicing Modifier**
SPINRAZA, RG7916, and branaplam all modulate the splicing of SMN2 RNA to increase the inclusion of exon 7 and results in an increase in the amount of functional SMN protein produced from the SMN2 transcript\(^\text{20,21,22,23}\).

**Neuroprotectant**
Neuroprotectants protect against neuronal injury or degradation. Olexosime is a neuroprotectant. Its mechanism of action is not fully understood but it likely acts on mitochondrial proteins by preventing excessive permeability of the mitochondrial membrane under stress conditions\(^\text{8,24}\). Olesoxime does not upregulate SMN levels.
CK-2127107 is a fast skeletal muscle troponin activator (FSTA) that amplifies the response of certain muscle fibers in response to motor neuron input\textsuperscript{25}. CK-2127107 does not upregulate SMN levels.

Intravenous delivery is a route of administration of drugs through a vein.

Intrathecal administration is a route of administration for drugs into the cerebrospinal fluid that surrounds spinal cord and brain via a lumbar puncture performed in the lower back. It may result in side effects such as headache, back pain, and transient or persistent cerebrospinal fluid leakage. In some cases, scoliosis could hinder the success of intrathecal delivery and may require special imaging during the procedure\textsuperscript{26}. Intravenous (IV), inhaled, or local anesthesia/sedation is routinely used for lumbar punctures, and the administration is performed in a hospital or clinic setting. ASOs have difficulty crossing the blood-brain barrier into the central nervous system (CNS) where motor neurons reside\textsuperscript{27,28}.

Oral delivery is a route of administration where a drug is taken through the mouth.

Gene therapy is an experimental technique to treat or prevent disease by inserting a gene into a patient’s cells\textsuperscript{29}.
Glossary

**ASO**

An antisense oligonucleotide is a short nucleic acid polymer (usually of 25 nucleotides or fewer) that binds to the specific RNA sequence of a gene target. ASOs are produced by chemical synthesis.

**Small Molecule**

A small molecule is a low molecular weight organic compound that can bind to and alter the activity or function of proteins, DNA, or RNA. Most therapeutic drugs are small molecules. Small molecules are produced by chemical synthesis.

**Systemic**

Systemic means the drug is distributed throughout the entire body, including the CNS, rather than restricted to a single organ/tissue. RG7916, branaplam, olexosime, AVXS-101, and CK-2127107 have systemic distribution.¹ ⁵ ⁷ ⁸ ¹⁷ ²³ ³⁰

**CNS Only**

CNS only means that the drug is mainly distributed in the central nervous system (brain and spinal cord). Distribution of SPINRAZA is mainly restricted to CNS.
References

7. https://clinicaltrials.gov, NCT02268552